Abstract 255P
Background
MEX3A is an evolutionarily conserved RNA-binding protein (RBP), of which functions and target genes in mammals remain largely unknown. Also, no previous study has shown the role of MEX3A in endometrial cancer.
Methods
We screened the differentially expressed genes (DEGs) and miRNAs (DEmiRs) between endometrial cancer samples and paired adjacent noncancerous endometrium samples with RNA-seq data. Then, we used package clusterProfiler to profile the GO and KEGG enrichment analysis of the most highly correlated genes with MEX3A, as well as the overlap genes with up-regulated DEGs. We evaluated the prognostic effect of genes using the Kaplan-Meier Plotter database. MEX3A tissue-specific expression was analyzed via the Human Protein Atlas database and TIMER. Methylation analysis was generated by MethHC and Wanderer.
Results
The volcano plot of DEmiRs showed a significant reduction in tumor suppressor miR-139 in tumor tissues compared to normal tissues. We totally identified 422 target genes of miR-139-5p using the prediction software TargetScan (7.1 version). MEX3A was one of the seven overlapping genes that we got between the miRNA target genes and the 842 up-regulated DEGs. MEX3A was significantly overexpressed in many types of tumor tissues, and interestingly, it had the highest expression in the female tissues. In addition, high MEX3A expression was significantly correlated with poor OS and progression-free survival (PFS) in endometrial cancers (OS HR = 2.07, P = 0.0021; PFS HR = 2.11, P = 0.0047). The GO analysis of top 5% most highly correlated genes with MEX3A in endometrial cancer revealed that biology processes associated with RNA splicing were mainly enriched. Simultaneously, the most enriched pathway was spliceosome, which indicated that the RBP may play an important role in the RNA splicing. Meanwhile, the MEX3A promoter region in the tumor tissue was hypomethylated compared to normal tissue. In addition, the MEX3A promotor differential methylation level is negatively correlated with MEX3A mRNA expression (corr = -0.512).
Conclusions
These findings suggest MEX3A is a potential prognostic biomarker in endometrial cancer and might play an oncogenic role as a novel cancer-critical splicing factor.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The author.
Funding
Has not received any funding.
The author has declared no conflicts of interest.
Resources from the same session
371P - Clinical utility of Encyclopedic tumour analysis to treat patients advanced refractory head and neck cancers
Presenter: Rajnish Nagarkar
Session: Poster display session
Resources:
Abstract
372P - Real-world fusion landscape in advanced Chinese pancreatic cancer using next generation sequecing: A multicenter study
Presenter: Yiyu Shen
Session: Poster display session
Resources:
Abstract
373P - Molecular profiling of non-small cell lung cancer (NSCLC) in Asia with targeted next-generation sequencing (NGS): Interim analysis of a co-operative group study (ATORG-001)
Presenter: Aaron Tan
Session: Poster display session
Resources:
Abstract
374P - Circulating tumour DNA (ctDNA) identifies actionable genetic alterations in Middle Eastern and Asian (MEA) patients diagnosed with carcinoma of unknown primary (CUP)
Presenter: Nir Peled
Session: Poster display session
Resources:
Abstract
375P - Whole-exome sequencing of tumour-only samples reveals the association between somatic alterations and clinical features in pancreatic cancer
Presenter: Huixin Lin
Session: Poster display session
Resources:
Abstract
376P - Adoption of molecular testing in breast cancer in a tertiary care center in a developing country
Presenter: Prasanta Dash
Session: Poster display session
Resources:
Abstract
377P - NGS in advanced NSCLC in a developing country: Ready for prime time?
Presenter: Amrith B P
Session: Poster display session
Resources:
Abstract
378P - Germline BRCA1/2 testing: Trend in Tan Tock Seng Hospital Singapore
Presenter: Chia Wei Lim
Session: Poster display session
Resources:
Abstract
379P - Study of germline mutations in high risk cancer patients from a tertiary care center in India
Presenter: Padmaj Kulkarni
Session: Poster display session
Resources:
Abstract
380P - Ventricular–Subventricular zone involvement: A predictive factor for survival in glioblastoma
Presenter: Vibhay Pareek
Session: Poster display session
Resources:
Abstract